- Home
- ESS vs JAZZ Comparison
ESS vs JAZZ Comparison
Compare ESS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESS | JAZZ |
|---|---|---|
| Founded | 1971 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4B | 15.6B |
| IPO Year | 1996 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ESS | JAZZ |
|---|---|---|
| Price | $293.88 | $253.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 14 |
| Target Price | ★ $279.90 | $217.57 |
| AVG Volume (30 Days) | 383.9K | ★ 789.8K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.65 | ★ 4.43 |
| Revenue | ★ $1,887,345,000.00 | $1,618,693,000.00 |
| Revenue This Year | $1.84 | $6.22 |
| Revenue Next Year | $3.35 | $7.68 |
| P/E Ratio | $178.01 | ★ $54.96 |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $238.46 | $105.00 |
| 52 Week High | $303.35 | $250.49 |
Technical Indicators
Market Signals| Indicator | ESS | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 55.42 | 65.44 |
| Support Level | $290.83 | $222.49 |
| Resistance Level | $303.35 | N/A |
| Average True Range (ATR) | 5.37 | 7.53 |
| MACD | -0.80 | 0.49 |
| Stochastic Oscillator | 23.25 | 99.98 |
Price Performance
Historical ComparisonAbout ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 259 apartment communities with over 63,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.